Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Training European Health Care Providers in Adolescent and Young Adult (AYA) Oncology: The Joint Action Networks of Expertise (JANE) on AYA with Cancer Perspective.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026

Same author

Correction: ASO Visual Abstract: Well‑Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes.

Annals of surgical oncology·2026

Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

ASO Visual Abstract: Well-Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes.

Annals of surgical oncology·2026

Same author

Well-Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes.

Annals of surgical oncology·2026

Same author

Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study.

The Lancet. Oncology·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Trabectedin therapy for sarcomas.

Paolo G Casali¹, Roberta Sanfilippo, Maurizio D'Incalci

¹Adult Sarcoma Medical Unit, Istituto Nazionale Tumori, Milan, Italy. paolo.casali@istitutotumori.mi.it

Current Opinion in Oncology

|May 22, 2010

Summary

This summary is machine-generated.

Trabectedin shows efficacy in adult soft-tissue sarcomas (STS), particularly leiomyosarcomas and liposarcomas. This marine-derived drug offers a histology-driven approach, with ongoing research to optimize its use.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Jun 12, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Area of Science:

Oncology
Pharmacology

Background:

Adult soft-tissue sarcomas (STS) exhibit diverse histology, necessitating tailored therapeutic strategies.
The development of novel chemotherapeutic agents has expanded treatment options for STS.

Purpose of the Study:

To evaluate the efficacy and tolerability of trabectedin in adult soft-tissue sarcomas.
To explore the role of histology and DNA repair mechanisms in predicting trabectedin response.

Main Methods:

Review of clinical data on trabectedin use in various STS subtypes.
Analysis of tumor response patterns and mechanisms of action, particularly in myxoid liposarcomas.
Investigation of DNA repair mechanisms as potential predictive biomarkers.

Main Results:

Trabectedin demonstrates significant efficacy in leiomyosarcomas, liposarcomas, and translocation-related sarcomas.
Distinct antitumor activity and a unique mechanism of action are observed in myxoid liposarcomas.
Trabectedin is generally well-tolerated as a single agent, with myelosuppression manageable through patient selection and supportive care.

Conclusions:

Trabectedin is a valuable addition to the histology-driven treatment of STS.
Further research is warranted to fully define its role across all STS subtypes and to optimize its tolerability profile.